Thalidomide for rheumatic disease: The best of both worlds?

Nature Clinical Practice Rheumatology

Volumn 3, Issue 6, 2007, Pages 308-309

  Lehman, Thomas J A ^a,b  

^a Cornell University ^*  (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANKYLOSING SPONDYLITIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; ENZYME ACTIVATION; ERYTHEMA NODOSUM LEPROSUM; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; IMMUNOMODULATION; INFECTION RISK; JUVENILE RHEUMATOID ARTHRITIS; LUNG EMBOLISM; MULTIPLE MYELOMA; NEPHROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATIC DISEASE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TERATOGENICITY;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; THALIDOMIDE;

EID: 34249871359     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0504     Document Type: Review

References (12)

1. Dixon WG et al. (2006) Rates of serious infection, including site-specific and bacterial intracellular infection in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 2368-76
2. Listing J et al. (2005) Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 52: 3403-3412
3. Stephens TD and Brynner R (2001) Dark Remedy: The impact of thalidomide and its revival as a vital medicine. New York: Perseus Books
4. 2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester. J Immunol 168 2644-2651
5. Sampaio EP et al. (1993) The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 168: 408-414
6. Thompson C (1995) Thalidomide effective for AIDS-related oral ulcers. Lancet 346: 1289
7. + subset. J Exp Med 187: 1885-1892
8. Lehman TJ et al. (2002) Thalidomide therapy for recalcitrant systemic onset juvenile rheumatoid arthritis. J Pediatr 140: 125-127
9. Keesal N et al. (1999) Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 26: 2344-2347
10. Huang F et al. (2002) One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis Rheum 47: 249-254
11. Anderson KC (2003) Moving disease biology from the lab to the clinic. Cancer 97: 796-801
12. LeBlanc R et al. (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103: 1787-1790